MarketPulse
M

$MAIA

4 articles found
4 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Diamond Equity Research

MAIA Biotech Raises $30M, Eyes 2026 Milestones with Ateganosine Trial Data

MAIA Biotech secures $30M funding and FDA Fast Track designation for ateganosine cancer therapy, with Phase 2 data showing 17.8-month median survival.
MAIAclinical developmentPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

MAIA Biotech Raises $30M in Public Offering to Fund Clinical Trials

MAIA Biotechnology closes $30M public offering of 20M shares at $1.50/share, funding clinical trials and operations.
MAIApublic offeringcommon stock
GlobeNewswire Inc.GlobeNewswire Inc.··Na

MAIA Biotech Raises $30M via Stock Offering to Fund Clinical Trials

MAIA Biotechnology prices $30M public offering at $1.50/share to fund clinical trials. Offering closes March 4, 2026.
MAIApublic offeringcommon stock
GlobeNewswire Inc.GlobeNewswire Inc.··Maia Biotechnology, Inc.

MAIA Biotech Taps Capital Markets for Cancer Drug Development Push

MAIA Biotechnology launches underwritten public offering of common stock and pre-funded warrants to fund clinical trials for its lead cancer therapy ateganosine.
MAIAclinical developmentpublic offering